Zhibin Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhibin Yu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Chang Wang
State Key Laboratory of Catalysis Dalian Institute of Chemical Physics Chinese Academy of Sciences Dalian Liaoning 116023 China
1 shared publication- Changrui Lu
Department of Molecular Biology and Genetics, 251 Biotechnology Building, Cornell University, Ithaca, NY 14853, USA
1 shared publication - Chunxia Hu
Wuhan Institute of Biological Products Co., LTD (WIBP)
1 shared publication Fangjingwei Xu
China National Biotec Group (CNBG)
1 shared publication- Fei Liu
China National Biological Group-Virogin Biotech (Shanghai) Ltd (CNBG-Virogin)
1 shared publication - Fujun Hou
Virogin Biotech (Shanghai) Ltd (Virogin)
1 shared publication
Latest Publications
- Open Access
- 14 June 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (35) , e2404046
Visualizing Phase Evolution of Co2C for Efficient Fischer–Tropsch to Olefins
Cobalt carbide (Co2C) possesses high catalytic efficiency Fischer–Tropsch synthesis (FTS), while the products selectivity appears sensitive to crystallography geometry. Since the Anderson–Schulz–Flory (ASF) distribution in FTS is broken through fabricating facetted Co2C nanocrystals, yet the underlying mechanism of Co2C crystallization remains unclarified suffering from sophisticated catalyst composition involving promoter agents. Herein, the synthesis of high‐purity single‐crystal nanoprisms (Co2C‐p) for highly efficient FTS is reported to lower olefins. Through comprehensive microstructure analysis, e.g., high‐resolution TEM, in situ TEM and electron diffraction, as well as finite element simulation of gas flow field, for the first time the full roadmap of forming catalytic active cobalt carbides is disclosed, starting from reduction of Co3O4 precursor to CoO intermediate, then carburization into Co2C‐s and subsequent ripening growth into Co2C‐p. This gas‐induced engineering of crystal phase provides a new synthesis strategy, with many new possibilities for precise design of metal‐based catalyst for diverse catalytic applications.
- 14 June 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (35) , e2404046
Open AccessVisualizing Phase Evolution of Co2C for Efficient Fischer–Tropsch to Olefins
Cobalt carbide (Co2C) possesses high catalytic efficiency Fischer–Tropsch synthesis (FTS), while the products selectivity appears sensitive to crystallography geometry. Since the Anderson–Schulz–Flory (ASF) distribution in FTS is broken through fabricating facetted Co2C nanocrystals, yet the underlying mechanism of Co2C crystallization remains unclarified suffering from sophisticated catalyst composition involving promoter agents. Herein, the synthesis of high‐purity single‐crystal nanoprisms (Co2C‐p) for highly efficient FTS is reported to lower olefins. Through comprehensive microstructure analysis, e.g., high‐resolution TEM, in situ TEM and electron diffraction, as well as finite element simulation of gas flow field, for the first time the full roadmap of forming catalytic active cobalt carbides is disclosed, starting from reduction of Co3O4 precursor to CoO intermediate, then carburization into Co2C‐s and subsequent ripening growth into Co2C‐p. This gas‐induced engineering of crystal phase provides a new synthesis strategy, with many new possibilities for precise design of metal‐based catalyst for diverse catalytic applications.
- Open Access
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV). The ZSVG-02-O induces neutralizing antibodies that effectively cross-react with Omicron subvariants following an order of BA.1>BA.2>BA.4/5. In naïve animals, ZSVG-02 or ZSVG-02-O induce humoral responses skewed to the vaccine’s targeting strains, but cellular immune responses cross-react to all variants of concern (VOCs) tested. Following heterologous prime-boost regimes, animals present comparable neutralizing antibody levels and superior protection across all VOCs. Single-boost only generated ancestral and omicron dual-responsive antibodies, probably by “recall” and “reshape” the prime immunity. New Omicron-specific antibody populations, however, appeared only following the second boost with ZSVG-02-O. Overall, our results support a heterologous boost with ZSVG-02-O, providing the best protection against current VOCs in inactivated virus vaccine– primed populations.
Open AccessHeterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV). The ZSVG-02-O induces neutralizing antibodies that effectively cross-react with Omicron subvariants following an order of BA.1>BA.2>BA.4/5. In naïve animals, ZSVG-02 or ZSVG-02-O induce humoral responses skewed to the vaccine’s targeting strains, but cellular immune responses cross-react to all variants of concern (VOCs) tested. Following heterologous prime-boost regimes, animals present comparable neutralizing antibody levels and superior protection across all VOCs. Single-boost only generated ancestral and omicron dual-responsive antibodies, probably by “recall” and “reshape” the prime immunity. New Omicron-specific antibody populations, however, appeared only following the second boost with ZSVG-02-O. Overall, our results support a heterologous boost with ZSVG-02-O, providing the best protection against current VOCs in inactivated virus vaccine– primed populations.